All In MedTech

Device Trial Radar · NCT07857343

CardioFlow Transcatheter Mitral Valve Replacement System Pre-market Clinical Investigation

A Prospective, Multicenter, Single-arm Clinical Investigation for the Evaluation of Safety and Effectiveness of Microport CardioFlow Transcatheter Mitral Valve Replacement System in the Treatment of Moderate to Severe or Severe Symptomatic Mitral Regurgitation(CF-TMVR)

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

152

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Jan 1, 2030

Study completion Jan 1, 2035

Sponsor

Lead sponsor
Shanghai MicroPort CardioFlow Medtech Co., Ltd.Not on our public-company list
Sponsor type
Industry
First posted
Oct 5, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, multi-center, single-arm study to assess the safety and effectiveness of Microport CardioFlow Transcatheter Mitral Valve Replacement system in the treatment of moderate to severe or severe degenerative mitral regurgitation and to provide the clinical evidence for product registration in China or other countries

Conditions

  • Degenerative Mitral Regurgitation

Interventions

  • Microport CardioFlow Mitral Valve Replacement SystemDevice

    Patients will undergo transcatheter mitral valve replacement using Microport CardioFlow Mitral Valve Replacement System. The device is delivered via a transapical approach under the guidance of medical imaging equipment; the valve product loaded within the delivery system is advanced to the mitral annulus and released, thereby replacing the native mitral valve with pathological changes in function or anatomy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of cumulative all-cause mortality at 12 months post-procedureTime frame: 12 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Cardiology

    Beijing, China

  • Cardiology

    Kunming, China

  • Cardiology

    Zhengzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.